Provided by Tiger Fintech (Singapore) Pte. Ltd.

Xeris Pharmaceuticals Inc

4.95
-0.0600-1.20%
Post-market: 4.970.0200+0.40%16:59 EDT
Volume:3.01M
Turnover:14.74M
Market Cap:792.77M
PE:-16.45
High:5.02
Open:4.94
Low:4.70
Close:5.01
Loading ...

Xeris Pharmaceuticals (XERS) Gets a Buy from Oppenheimer

TIPRANKS
·
09 May

Stock Track | Xeris Pharmaceuticals Soars 5.02% on Record Q1 Revenue and Positive Outlook

Stock Track
·
08 May

BRIEF-Xeris Biopharma Q1 Net Income USD -9.22 Million

Reuters
·
08 May

Xeris Biopharma Q1 Basic EPS USD -0.06

THOMSON REUTERS
·
08 May

Press Release: Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

Dow Jones
·
01 May

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit

Simply Wall St.
·
26 Apr

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

GlobeNewswire
·
17 Apr

BRIEF-Xeris Announces Changes To Its Board Of Directors

Reuters
·
28 Mar

Xeris Announces Changes to Its Board of Directors

THOMSON REUTERS
·
28 Mar

Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?

Insider Monkey
·
27 Mar

Don't Ignore The Insider Selling In Xeris Biopharma Holdings

Simply Wall St.
·
23 Mar

Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?

Zacks
·
20 Mar

Xeris Biopharma Says US FDA Approves Gvoke VialDx for Diagnostic Use

MT Newswires Live
·
17 Mar

Xeris Biopharma Holdings Inc - Gvoke Vialdx Expected to Be Available in Q3 2025

THOMSON REUTERS
·
17 Mar

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

Business Wire
·
17 Mar

Xeris Biopharma Is Maintained at Buy by Craig-Hallum

Dow Jones
·
10 Mar

Xeris Biopharma price target raised to $6 from $5 at Leerink

TIPRANKS
·
08 Mar